Loading patent…
AssigneeMorphogenesis, Inc.
InventorsMichael J.P. Lawman, Patricia Lawman
Estimating the term…
The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoictic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.
A polynucleotide molecule that encodes a polypeptide, or a fragment or variant thereof, expressed on the surface of a subset of human hematopoietic mononuclear cells, wherein said polypeptide immunoreacts with MG1 antibody.
A human cell population substantially enriched for hematopoictic cells expressing the MG1 antigen and substantially free of mature myeloid and lymphoid cells.
A method for treating a malignant tumor in a patient, said method comprising administering an effective amount of an antibody to said patient that binds to an MG1 antigen.
A method for providing genetic therapy for a condition treatable by gene therapy, said method comprising selecting a population of human cells substantially enriched for hematopoietic cells expressing an MG1 antigen, and introducing into the genome of said selected cell population a gene or polynucleotide molecule that can provide genetic therapy to correct or ameliorate said condition.
A method for providing genetic therapy for a condition treatable by gene therapy, said method comprising administering an effective amount of a gene therapy vector to a person in need of such treatment, said vector comprising an antibody that binds to an MG1 antigen and further comprising a gene or polynucleotide molecule that can provide genetic therapy to correct or ameliorate said condition, wherein said vector binds to target cells expressing said MG1 antigen and said gene or polynucleotide molecule that can provide genetic therapy is introduced into the genome of said target cell expressing said MG1 antigen.
Dependencies are inferred from the claim text.